Comparison
Linaclotid vs. Teriparatid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
851199-59-2
52232-67-4
Molecular weight
1526.74 g/mol
4117.8 g/mol
Half-life
no data
1 h
Sequence
no data
Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-PheMechanism of action
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Teriparatid
Teriparatide corresponds to the biologically active first 34 amino acids of human parathyroid hormone and binds the PTH-1 receptor on bone and kidney cells. The literature describes that intermittent receptor activation preferentially stimulates the activity of bone-forming osteoblasts, whereas continuously elevated PTH exposure (as in hyperparathyroidism) tends to favor bone resorption. This time-dependent difference is regarded as the mechanistic basis for the bone-anabolic effect observed in studies.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
0
4
of which in humans
0
4
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Linaclotid and Teriparatid?
- Linaclotid is classified as "Research other", while Teriparatid is classified as "Research other". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Teriparatid: Teriparatide is the recombinant N-terminal fragment 1-34 of human parathyroid hormone (PTH). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis. Unlike antiresorptive agents, studies attribute to it an effect that stimulates new bone formation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Linaclotid or Teriparatid?
- The highest available evidence level is "Human RCT" for Linaclotid and "Human RCT" for Teriparatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Linaclotid and Teriparatid in Germany and the United States?
- Germany: Linaclotid — Prescription, Teriparatid — Prescription. United States: Linaclotid — Prescription, Teriparatid — Prescription. These are factual summaries with source and review date on the individual pages.